{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kyler KE"],"funding":["Eunice Kennedy Shriver National Institute of Child Health and Human Development","NICHD NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","NIDDK NIH HHS"],"pagination":["e13782"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11022290"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(4)"],"pubmed_abstract":["In this brief report, we provide an analysis of the influence of a novel CYP2C haplotype (CYP2C:TG) on proton pump inhibitor (PPI) pharmacokinetics (PK) in children. The CYP2C:TG haplotype has been proposed to be associated with increased CYP2C19 activity. We sought to determine if this CYP2C:TG haplotype resulted in similar alterations in metabolism for proton pump inhibitors, which are primarily metabolized by CYP2C19. In a cohort of 41 children aged 6-21 participating in a PPI pharmacokinetic study, effects of the CYP2C:TG allele were assessed by fitting two linear regression models for each of the six PK outcomes assessed, the second of which accounted for the presence of the CYP2C:TG allele. The difference in R<sup>2</sup> values between the two models was computed to quantify the var"],"journal":["Clinical and translational science"],"pubmed_title":["Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children."],"pmcid":["PMC11022290"],"funding_grant_id":["K23 DK115827","T32 HD069038"],"pubmed_authors":["Leeder JS","Staggs VS","Pearce RE","Kyler KE","Abdel-Rahman S","Gaedigk A","Toren P","Shakhnovich V"],"additional_accession":[]},"is_claimable":false,"name":"Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children.","description":"In this brief report, we provide an analysis of the influence of a novel CYP2C haplotype (CYP2C:TG) on proton pump inhibitor (PPI) pharmacokinetics (PK) in children. The CYP2C:TG haplotype has been proposed to be associated with increased CYP2C19 activity. We sought to determine if this CYP2C:TG haplotype resulted in similar alterations in metabolism for proton pump inhibitors, which are primarily metabolized by CYP2C19. In a cohort of 41 children aged 6-21 participating in a PPI pharmacokinetic study, effects of the CYP2C:TG allele were assessed by fitting two linear regression models for each of the six PK outcomes assessed, the second of which accounted for the presence of the CYP2C:TG allele. The difference in R<sup>2</sup> values between the two models was computed to quantify the var","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-02T08:19:46.682Z","creation":"2026-05-26T03:06:48.32Z"},"accession":"S-EPMC11022290","cross_references":{"pubmed":["38629502"],"doi":["10.1111/cts.13782"]}}